Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)

NCT04052828 | Completed FDA Device

• 1 other identifier: HUM00159792
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single site pilot trial to assess the feasibility and safety of treating severe CDH with Fetal Endoscopic Tracheal Occlusion with the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) at Michigan Medicine. The study will enroll pregnant women that meet study criteria. Participants will have placement of FETO between gestational age at 27 weeks plus 0 days and 29 weeks 6 days. The timing for removal of FETO will ideally be between 34 weeks 0 days and 34 weeks and 6 days but ultimately decided by the Fetal Diagnosis and Treatment Center at Michigan Medicine. This study requires that study participants live within 30 miles of the Von Voigtlander Women's Hospital and C.S. Mott Children's Hospital in order to maintain weekly follow up appointments while the balloon is in place and up to delivery. Additionally, there are lifestyle considerations where participants would be unable to carry on normal daily activities including exercise and sexual intercourse, not be able to work the remainder of the pregnancy, as well as have a support person that is available to stay with such as a spouse, friend, partner, parent.

Conditions

Congenital Diaphragmatic Hernia

Keywords

pregnant; fetal endoscopic tracheal occlusion

Outcome Measures

Primary Outcomes (2)

• Number of successful placements of the Goldballoon Detachable Balloon (GOLDBAL2) at gestational age 27 weeks zero days (27w0d) to 29 weeks and 6 days (29w6d) gestation.

  Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.

  27w0d - 29w6d

• Number of successful retrievals of the GOLDBAL2

  This will ideally occur around the 34th week of gestation and have the balloon removed prior to delivery.

  Removal prior to delivery approximately 34 weeks of gestation

Secondary Outcomes (5)

• Change in observed to expected total fetal lung to head ratios (o/e TFLV) on prenatal magnetic resonance imaging (MRI)

  baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval

• Change in fetal lung growth

  baseline (before balloon placement), immediately prior to balloon retrieval

• Gestational age at delivery

  At the time of delivery (up to approximately 34 weeks)

• Survival of infant to hospital discharge or 180 days after hospitalized

  Discharge from hospital or up to 180 days in the hospital

• Number of maternal complications

  up to 4-6 weeks postpartum

Study Arms (1)

FETO with GOLDBAL2

EXPERIMENTAL

A balloon will be placed in the airway of the fetus during the FETO procedure.

Device: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)

Interventions

FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) DEVICE

This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.

FETO with GOLDBAL2

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Pregnant women
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed and dated consent
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Singleton pregnancy
• No pathogenic variants on microarray or pathologic findings on karyotype
• Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects
• Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as observed-to-expected (o/e) lung to head ratios (LHR) \<25% with liver up
• Gestational age at FETO procedure: if o/e LHR \<25% will be done at 27 weeks plus 0 days to 29 weeks plus 6 days
• Meets psychosocial criteria
• Willing to reside within 30 minutes of Von Voigtlander Women's Hospital and ability to maintain follow up appointments
• Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near Von Voigtlander Women's Hospital
• Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work.

You may not qualify if:

• Multi-fetal pregnancy
• History of latex allergy
• History of preterm labor or incompetent cervix (requiring cerclage), short cervix (≤20mm), or uterine anomaly predisposing to preterm labor
• Bilateral CDH, unilateral CDH with o/e LHR \> 25%, or unilateral CDH with o/e LHR \<25% but liver completely down in abdomen
• Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome
• Maternal contraindications to elective fetoscopic surgery
• Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery
• Maternal isoimmunization or neonatal alloimmune thrombocytopenia
• Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure
• No safe or feasible fetoscopic approach to balloon placement
• Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate.

Sponsors & Collaborators

• Dr Erin Perrone: lead

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Hernias, Diaphragmatic, Congenital

Condition Hierarchy (Ancestors)

Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hernia, Diaphragmatic; Internal Hernia; Hernia; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Erin Perrone, MD

  University of Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor of Surgery

Study Record Dates

• First Submitted: August 8, 2019
• First Posted: August 12, 2019
• Study Start: April 5, 2021
• Primary Completion: August 12, 2025
• Study Completion: October 16, 2025
• Last Updated: June 3, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)